Castle Biosciences (NASDAQ:CSTL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. […]
Parallel Advisors LLC decreased its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) by 50.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 21,769 shares of the company’s stock after selling 21,791 shares during the quarter. Parallel Advisors LLC owned 0.09% […]
Wall Street brokerages expect that Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) will report $25.13 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Castle Biosciences’ earnings. The lowest sales estimate is $24.90 million and the highest is $25.35 million. Castle Biosciences reported sales of $22.81 million in the […]
Castle Biosciences (NASDAQ:CSTL – Get Rating) had its price objective trimmed by Robert W. Baird from $82.00 to $60.00 in a research note issued to investors on Tuesday, The Fly reports. A number of other equities analysts have also weighed in on CSTL. Stephens assumed coverage on Castle Biosciences in a research report on Friday, […]
Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) Director Daniel Bradbury sold 8,852 shares of the firm’s stock in a transaction on Tuesday, February 22nd. The shares were sold at an average price of $39.02, for a total value of $345,405.04. The sale was disclosed in a document filed with the SEC, which is available through […]